GlassScriptPhysician profile
Hui-Li Huang
NPI 1851476972
$41,250.71
in general payments reported to CMS, 2019-2025
41 companies · $5,426 in 2025
The $5,426 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,827 · 2020: $3,827 · 2021: $7,245 · 2022: $6,470 · 2023: $5,796 · 2024: $4,659 · 2025: $5,426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,880.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $5,991.09 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Teva Pharmaceuticals USA, INC. | $5,830.07 | 2019-2024 | Uzedy, Austedo Xr, Austedo |
| Astrazeneca Pharmaceuticals LP | $4,728.70 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $4,527.03 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $3,763.36 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $1,951.44 | 2019-2023 | Spravato |
| Biohaven Pharmaceuticals, INC. | $1,517.75 | 2021 | |
| Amgen INC. | $1,375.53 | 2019-2024 | Repatha, Otezla |
| E.R. Squibb & Sons, L.L.C. | $999.91 | 2022-2025 | Cobenfy, Camzyos |
| Esperion Therapeutics, INC. | $874.06 | 2020-2023 | Nexlizet, Nexletol |
| Lilly USA, LLC | $844.01 | 2019-2025 | Kisunla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $760.31 | 2019-2022 | |
| Glaxosmithkline, LLC. | $714.71 | 2019-2025 | Arexvy, Shingrix |
| Axsome Therapeutics, INC. | $613.87 | 2024-2025 | Auvelity, Symbravo |
| Otsuka America Pharmaceutical, INC. | $596.26 | 2022-2025 | Abilify Asimtufii, Abilify Maintena |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hui-Li Huang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.